Fetal Stem Cells
Historically prominent in parts of Europe, without an approved product or controlled efficacy evidence.
No approved product
What it actually is
Fetal stem cells are early-lineage cells obtained from fetal tissue. They are more proliferative than adult stem cells and less immunogenic than mature tissue, and they occupy a developmental position between embryonic and adult cells. Several long-running European clinics were built on them, which is why the label still appears in patient-facing marketing more often than in current clinical literature.
Where it comes from
Fetal tissue, obtained following termination of pregnancy. Consent, procurement chain and traceability are the central issues, and they are regulated differently across jurisdictions. This sourcing question is not incidental — it determines whether the material can be used lawfully at all.
How it is made — and what can go wrong
Processing varies widely between providers and is frequently not published. Where suspensions or extracts are prepared rather than characterised cell products, the composition of what is administered may not be defined in the way a medicine's composition is defined.
Regulatory status
There is no EMA-authorised fetal stem cell medicine. The International Society for Stem Cell Research has written to both FDA and EMA seeking stronger enforcement against clinics offering unproven stem-cell interventions, and this category features in that concern. Peer-reviewed analysis has documented how EU advanced-therapy rules have been used by clinics in ways the framework did not intend.
What the evidence shows
The published record is dominated by case series and provider-reported outcomes. Randomised controlled evidence for the indications typically marketed — including neurodevelopmental and neurodegenerative conditions — is absent.
Limits worth knowing
No approval, no standardised product, limited independent characterisation, and unresolved ethical and legal questions around sourcing. Where a provider markets fetal cells for autism, cerebral palsy or intellectual disability, no controlled evidence supports those uses.
What this could actually be used for
Cells taken from fetal tissue: biologically immature, with high proliferative capacity and, in some tissues, an already-committed identity that adult sources cannot supply.
The rationale offered is potency and immaturity — younger cells expand more readily and are argued to provoke a weaker immune response than adult equivalents. Whether that translates into anything clinical is precisely what the registry does not currently show.
Liver and metabolic disease 1 study registered
The one place where a completed trial exists: fetal liver cells transplanted in chronic liver failure. The liver is chosen because it regenerates on its own, so a graft has to survive and contribute rather than rebuild an organ single-handedly. All cell therapy research registered for this condition →
Neurological conditions
Fetal neural tissue grafting in Parkinson disease is the historical origin of the entire cell-therapy field, and its results — some lasting benefit, some serious side effects, enormous variability between patients — are the reason manufactured, specified cells replaced it.
Broad regenerative and anti-ageing claims
This is the category most heavily marketed to international patients and the least represented in trial registries anywhere. The distance between how often it is sold and how often it is studied is the single most useful fact on this page.
Where it stops. Sourcing, consent and legal status vary enormously between countries, and the registry footprint is tiny relative to how widely this is advertised. The complete list of registered studies is below — it is short enough to publish in full, which itself says something.
What the registry actually shows for this cell type
Our own count of every study registered on ClinicalTrials.gov under this cell type, retrieved 2026-09-04. A registration is a declaration of intent, not a result — which is why the status column matters more than the total does.
| Status in the registry | Studies | Share |
|---|---|---|
| Completed | 2 | 50% |
| Status not updated by sponsor | 1 | 25% |
| Recruiting now | 1 | 25% |
| All registered studies | 4 | 100% |
Reading it: 2 studies carry no assigned trial phase, meaning they sit outside the phased development path that leads to an approved medicine; not one study has passed Phase 1; 2 studies sit at Phase 1 or earlier; 1 record have not had a status update from the sponsor and may be dormant. One sponsor, Assistance Publique - Hôpitaux de Paris, accounts for 1 of the 4 records, so this is closer to a single-programme field than an independently replicated one.
Every registered study for this cell type
At this size the complete list is shorter than any summary of it would be.
| Registry ID | Conditions | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07183384 | Preeclampsia, Postpartum, Endothelial Injury, Exosome Multiomics, Cell | Recruiting now | Phase 1/Phase 2 | Universitas Padjadjaran |
| NCT07169838 | Regenerative Medicine, Stem Cell Banking, Perinatal Medical Waste, Umb | Completed | none assigned | Kayseri City Hospital |
| NCT04903990 | Breast Cancer | Status not updated by sponsor | none assigned | Assistance Publique - Hôpitaux de Paris |
| NCT01013194 | Liver Cirrhosis | Completed | Phase 1/Phase 2 | The Mediterranean Institute for Transplantation and Advanced Specialized Therapies |
The directions above describe where the biology points and where research has been registered. They are not claims that any of it works, not evidence of benefit, and not a treatment recommendation. Counts are our own extraction from the ClinicalTrials.gov API, retrieved 2026-09-04; the queries behind them are published with the dataset so that anyone can repeat the count.
Conditions where this cell family is studied
Public registries do not carry a separate category for this sub-type. Studies using it are recorded under the broader mesenchymal stromal cell (MSC) heading, alongside bone marrow, adipose and umbilical sources. The counts below therefore describe the MSC family, which includes this preparation but is not limited to it.
From clinicaltrials.gov API v2, snapshot 2026-08-29. Dark overlay marks studies currently recruiting.
| Condition | Registered MSC studies | Recruiting now | Share |
|---|---|---|---|
| Knee osteoarthritis | 124 | 9 | 19% |
| Cirrhosis | 62 | 5 | 9% |
| Crohn disease / IBD | 52 | 6 | 8% |
| Stroke recovery | 45 | 7 | 7% |
| Spinal cord injury | 38 | 2 | 6% |
| Multiple sclerosis | 37 | 3 | 6% |
| Heart failure | 32 | 3 | 5% |
| Diabetes | 29 | 1 | 4% |
| ALS | 29 | 2 | 4% |
| Alzheimer disease | 23 | 6 | 4% |
| Lupus | 23 | 4 | 4% |
| Erectile dysfunction | 23 | 5 | 4% |
| All 26 conditions tracked | 657 | 74 | 100% |
657 registered studies across 26 conditions, of which 74 are recruiting. Knee osteoarthritis alone takes 19% of them. A provider offering this preparation for a condition near the bottom of the table is working far outside where the research sits.
One question the table cannot answer for you: ask which registered study used their preparation, from their tissue source, at their dose. A family-level count is not evidence for a specific product. The split across MSC, HSCT and exosomes is in the cell type by condition map.
What to ask before agreeing to anything
- What is the documented procurement and consent chain for the tissue?
- What is the defined composition of the administered material, and who characterised it?
- Which registered trial or authorisation covers this exact use?
- What independent, peer-reviewed controlled evidence exists for the proposed indication?
Sources behind the numbers on this page
- PubMed — Fetal Stem Cells
- ClinicalTrials.gov — registered studies
- EMA — advanced therapy medicinal products
- FDA — cellular and gene therapy products
Study counts above are our own extraction from ClinicalTrials.gov; the links let you reproduce them. Not medical advice, and not an assessment of whether any treatment is appropriate for you.